RVNC241220C2500
- 1.63
- 0.000.00%
Revance Therapeutics Newsroom
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Barclays Remains a Hold on Revance Therapeutics (RVNC)
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Cautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties With Crown Laboratories
Stifel Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.66
Revance Therapeutics Analyst Ratings
H.C. Wainwright Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $6.6
Needham Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Revance Therapeutics (RVNC) Gets a Hold From Needham
Needham Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Revance Therapeutics (RVNC) Gets a Hold From Mizuho Securities
Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Conmed (CNMD) and Revance Therapeutics (RVNC)
Guggenheim Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.66
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Revance Therapeutics Cut to Equal-Weight From Overweight by Barclays
Revance Therapeutics Analyst Ratings
Barclays Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $7
H.C. Wainwright Downgrades Revance Therapeutics(RVNC.US) to Hold Rating, Cuts Target Price to $6.6
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating